Non-Small Cell Lung Cancer

Circulating tumor DNA response to pembrolizumab can identify patients with molecular disease progression needing treatment intensification, according to the results of a phase II/III clinical trial. Circulating tumor DNA (ctDNA) has demonstrated promise in identifying primary resistance to immunotherapy. Concerning non-small cell lung cancer (NSCLC), where pembrolizumab and combination pembrolizumab–carboplatin–taxane/pemetrexed are the first-line options, it...

A recent literature review identifies promising therapeutic agents that have shifted the non-small cell lung cancer treatment paradigm. Lung cancer is the leading cause of cancer mortality worldwide. Research is rapidly evolving regarding the treatment of non-small cell lung cancer (NSCLC) with biomarker-driven targeted therapy and immunotherapy using checkpoint inhibitors.  A review of phase III...

Previous research has shown that Black patients with early-stage non-small cell lung cancer (NSCLC) experience worse overall survival than white patients. In an effort to rectify this disparity, researchers from the Dana-Farber Cancer Institute sought to determine why Black patients with NSCLC are less likely to undergo surgical treatment. The researchers used ten years of...

Hospice care provides patients with terminal illness with care that lessens the burden of illness and improves quality of life. Approximately 1.5 million Medicare recipients receive hospice care each year. Numbers have steadily increased over the last several years. Of these cases, about 98% involve routine home care services. There is concern as to why...

Prior research has revealed significant racial disparities in the diagnosis of lung cancer. Researchers from the University of Colorado examined differences in initial diagnostic imaging use and compared how these data relate to cancer-specific survival rates in Hispanic, non-Hispanic white, and non-Hispanic Black patients diagnosed with non-small cell lung cancer. The researchers collected data from...

In the United States, thousands of patients are treated for non-small cell lung cancer (NSCLC) each year. For localized NSCLC, there is a 63% 5-year survival rate. There is a 35% 5-year survival rate for regional NSCLC. With the improvements made in lung cancer treatment, including new targeted treatments and immunotherapies, patients with NSCLC are...

Evidence has shown that patients with lung cancer who do not receive guideline-concordant treatment experience worse outcomes. It is crucial that all patients are provided with treatment that meets appropriate clinical guidelines. Researchers from the University of Michigan examined the level of adherence to minimal lung cancer treatment guidelines recommended by the National Comprehensive Cancer Network...

Lung cancer has the highest mortality rate of all cancers. To improve patient survival rates, it is imperative that lung cancer is diagnosed early and that the most effective treatments are available and performed in a timely manner for all populations. Previous research has identified racial and sex-related disparities in the treatment of patients with...

It is more important now than ever to understand the factors that impact early detection and treatment of non-small cell lung cancer. The COVID-19 pandemic reduced access to preventive and diagnostic care, causing many Americans to delay cancer treatment. Researchers at the Washington University School of Medicine in St. Louis, Missouri sought to determine the...